Roche chief Schwan shoots down idea of Chugai sale; Could high court crumple gene patents?;

 @FierceBiotech: Firm ranks top 5 biotech deals in evolving pharma R&D landscape. Report | Follow @FierceBiotech

 @JohnCFierce: Another thought on $GSK: If it gets over tox issue, drisapersen is probably headed for approval, barring a nasty efficacy surprise in Ph3. | Follow @JohnCFierce.

 @RyanMFierce: Just heard from ex-FDA CIO Eric Perakslis. We'll have more on his next move soon, hopefully. News on his departure: Story | Follow @RyanMFierce

> Roche ($RHHBY) CEO Severin Schwann shot down ideas about his company selling off its stake in Japan's Chugai Pharmaceuticals in the wake of an underperforming yen. Article

> A U.S. Supreme Court decision on gene patents could shake up the IP landscape in the biotech industry. Report

> Thrombogenics expects to collect a €45 million euro payment from Novartis in connection with the launch of its eye treatment in Europe. Item

> The U.K's BTG says that the FDA has accepted the company's application for review of Varisolve for varicose veins, setting the stage for a potential approval next year. Report

> Synergy Pharmaceuticals ($SGYP) has raised $90.1 million in a follow-on stock sale. Item

Medical Device News

 @FierceMedDev: Dx startup On-Q-ity shuts down. DxExtra story | Follow @FierceMedDev

 @MarkHFierce: Altura Medical drew in $6M in new financing for AAA stent graft develpment, according to a regulatory filing. Story | Follow @MarkHFierce

 @DamianFierce: Boston Scientific is launching a new, FDA-approved neuromodulation device for chronic back pain. Article | Follow @DamianFierce

> Life Tech snags Korean reagents outfit amid bidding war. News

> Med tech industry blasts Obama's proposed FY 14 budget. Item

Pharma News

 @FiercePharma: More layoffs for $LLY: Eli Lilly to cut 100s of sales people in neuroscience, CV and men's health. Report | Follow @FiercePharma

 @EricPFierce: C'est la vie. Sanofi finds the politics of downsizing in France a war of attrition. Report | Follow @EricPFierce

> Bristol-Myers, Lilly expand biologics operations. More

> Elan investors approve share buyback but still must decide on buyout. Story

> Roche CEO says no need to buy out Japanese subsidiary Chugai. Item

And Finally… Amid all the buzz about parties interested in buying Life technologies ($LIFE), the life sciences company went out and purchased KDR Biotech, a provider of research reagents based in Seoul, Korea. Release

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.